Phase 1 First in Human Study of Programmed Cell Death Receptor-1 (PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs JTX 4014 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jounce Therapeutics
- 05 Nov 2019 Results presented in a Jounce Therapeutics media release.
- 01 Oct 2019 According to an Jounce Therapeutics media release, data from this study will be presented at the Society for Immunotherapy of Cancer's ( SITC) 34th Annual Meeting.
- 21 Aug 2019 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History